Clinical trial
Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With…
NCT00128739 · Rafa Laboratories, Industry · Completed
Key facts
| NCT number | NCT00128739 |
|---|---|
| Title | Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation |
| Official title | A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD |
| Lead sponsor | Rafa Laboratories, Industry |
| Collaborators | Dr. Falk Pharma GmbH Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Vs Host Disease |
| Intervention type | Drug |
| Interventions | Budesonide |
| Enrollment | 24 |
| Start date | Jan 1, 2001 |
| Completion | Aug 1, 2005 |
| First posted | Aug 10, 2005 |
| Last update posted | Aug 29, 2005 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: